论文部分内容阅读
针对抗高血压药物的合理应用,国际上作过许多大型安慰剂对照临床试验,而且其中多项临床试验比较了新药(ACEI,CCB,ARB)和传统药物(利尿剂,β受体阻滞剂)对终点事件的影响。客观、科学、综合地评价这些大型临床试验有助于更好地推动循证医学与临床实践相结合,提高广大医生的临床实践水平。本着这一宗旨,中华医学会英国医学杂志(BMJ)中文版编委会特邀请在京的著名心血管、肾脏及内分泌领域的专家于2003年4月7日在北京举办了“从几项大型临床试验看抗高血压药物的合理应用”高层专家座谈会。会议由中华医学会英国医学杂志(BMJ)中文版编委会主办,北京诺华制药有限公司协办,由中国医学科学院中国协和医科大学、北京协和医院方圻教授与中国医学科学院阜外心血管病医院高润霖院士担任主席,北京大学人民医院徐成斌教授回顾了抗高血压治疗领域的几项大型临床试验及国际上主要的抗高血压治疗指南,与会的高层专家就“抗高血压药物的合理应用”话题展开了讨论。现将专家们讨论的要点归纳如下,以期引起读者对这一热点问题的关注,共同促进我国高血压治疗领域的学术发展。
A number of large, placebo-controlled clinical trials have been conducted for the rational use of antihypertensives, and many of them have compared new drugs (ACEI, CCB, ARB) with traditional medicines (diuretics, beta blockers Impact on the end event. Objectively, scientifically and comprehensively evaluating these large-scale clinical trials will help to better promote the combination of evidence-based medicine and clinical practice, and enhance the clinical practice of doctors. In line with this aim, the Chinese Medical Editorial Board of the Chinese Medical Association (BMJ) invited specialists from the famous cardiovascular, kidney and endocrine fields in Beijing to hold the “ Clinical trials to see the rational use of antihypertensive drugs ”high-level expert forum. The symposium was sponsored by Chinese Medical Editorial Board of Chinese Medical Association (BMJ) and Novartis Pharmaceutical Co., Ltd. Beijing. The conference was co-sponsored by Chinese Academy of Medical Sciences Peking Union Medical College and Beijing Union Medical College Hospital and Professor Fu Fuwai of Chinese Academy of Medical Sciences Prof. Xu Runbin, Peking University People’s Hospital, reviewed several major clinical trials in the field of antihypertensive treatment and major international antihypertensive treatment guidelines. The top experts at the meeting discussed the topic of “rational use of antihypertensive drugs” Started a discussion. Now the experts discussed the main points are summarized below, with a view to arouse readers’ attention to this hot issue, to jointly promote the academic development of hypertension treatment in our country.